The store will not work correctly when cookies are disabled.
N-(N-(3,4-dichlorobenzyl)carbamimidoyl)-3,5,6-trimethylpyrazine-2-carboxamide
ID: ALA4174485
PubChem CID: 25216895
Max Phase: Preclinical
Molecular Formula: C16H17Cl2N5O
Molecular Weight: 366.25
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1nc(C)c(C(=O)NC(=N)NCc2ccc(Cl)c(Cl)c2)nc1C
Standard InChI: InChI=1S/C16H17Cl2N5O/c1-8-9(2)22-14(10(3)21-8)15(24)23-16(19)20-7-11-4-5-12(17)13(18)6-11/h4-6H,7H2,1-3H3,(H3,19,20,23,24)
Standard InChI Key: FSRQCKLTRWOBOD-UHFFFAOYSA-N
Molfile:
RDKit 2D
24 25 0 0 0 0 0 0 0 0999 V2000
21.2579 -9.2697 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2568 -10.0893 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.9648 -10.4982 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.6745 -10.0888 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.6717 -9.2661 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.9630 -8.8609 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.5501 -8.8613 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.3778 -8.8549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.5488 -10.4973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.3828 -10.4963 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.3841 -11.3135 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
24.0899 -10.0866 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.7983 -10.4940 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5053 -10.0843 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.7995 -11.3112 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.2137 -10.4918 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.9207 -10.0821 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6263 -10.4898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.3328 -10.0808 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.3320 -9.2627 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6187 -8.8554 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.9150 -9.2668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.0410 -10.4886 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
29.0385 -8.8521 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
1 7 1 0
5 8 1 0
2 9 1 0
4 10 1 0
10 11 2 0
10 12 1 0
12 13 1 0
13 14 1 0
13 15 2 0
14 16 1 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
19 23 1 0
20 24 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 366.25 | Molecular Weight (Monoisotopic): 365.0810 | AlogP: 3.16 | #Rotatable Bonds: 3 |
Polar Surface Area: 90.76 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 11.29 | CX Basic pKa: 7.28 | CX LogP: 2.10 | CX LogD: 1.86 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.57 | Np Likeness Score: -0.81 |
References
1. Zou J, Gao P, Hao X, Xu H, Zhan P, Liu X.. (2018) Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives., 147 [PMID:29432947] [10.1016/j.ejmech.2018.01.097] |